# A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

> **NCT01021423** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 9 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01021423
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-01
- **Primary completion:** 2011-03-01
- **Final completion:** 2011-03-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021423, "A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01021423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*